In 2014, 72 biotechnology firms that develop drugs, biologics and gene, stem or cell therapies grossed $5.7bn from initial public offerings in the US with most companies ending the year with stock values well above their IPO price – and values have risen higher in 2015.
In 2014, 72 biotechnology firms that develop drugs, biologics and gene, stem or cell therapies grossed $5.7bn from initial public offerings in the US with most companies ending the year with stock values well above their IPO price – and values have risen higher in 2015.
Even so, only eight therapeutics companies have launched first-time offerings this year versus the 22 biotech IPOs that hit the...
Create an account to read this article
Already a subscriber?
While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.
The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.
